ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
74.67
-2.48 (-3.21%)
Feb 27, 2026, 9:37 AM EST - Market open
ANI Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts that cover ANI Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $107.33, which forecasts a 43.74% increase in the stock price over the next year. The lowest target is $90 and the highest is $124.
Price Target: $107.33 (+43.74%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 16, 2026.
Analyst Ratings
The average analyst rating for ANI Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 | 3 | 3 |
| Buy | 3 | 3 | 2 | 3 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $115 → $124 | Strong Buy | Maintains | $115 → $124 | +66.06% | Jan 16, 2026 |
| Barclays | Barclays | Buy Initiates $100 | Buy | Initiates | $100 | +33.92% | Dec 9, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $114 → $115 | Strong Buy | Maintains | $114 → $115 | +54.01% | Nov 10, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $77 → $90 | Hold | Maintains | $77 → $90 | +20.53% | Oct 9, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $95 → $115 | Buy | Maintains | $95 → $115 | +54.01% | Sep 24, 2025 |
Financial Forecast
Revenue This Year
885.29M
from 614.38M
Increased by 44.10%
Revenue Next Year
1.00B
from 885.29M
Increased by 13.18%
EPS This Year
7.70
from -1.04
EPS Next Year
8.70
from 7.70
Increased by 12.95%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 915.4M | 1.1B | ||||
| Avg | 885.3M | 1.0B | ||||
| Low | 847.8M | 894.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 49.0% | 26.7% | ||||
| Avg | 44.1% | 13.2% | ||||
| Low | 38.0% | 1.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 8.03 | 10.21 | ||||
| Avg | 7.70 | 8.70 | ||||
| Low | 7.31 | 7.45 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 32.5% | ||||
| Avg | - | 12.9% | ||||
| Low | - | -3.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.